J. Holz

Publications29
h-index11
Citations787
Highly Influential Citations39
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Barbato
  • 523 Publications • 18,386 Citations
  • W. Wijns
  • 1,058 Publications • 99,345 Citations
  • J. Bartunek
  • 455 Publications • 18,202 Citations
  • J. George
  • 446 Publications • 27,402 Citations
  • Publications
  • Influence
Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results
TLDR
It is demonstrated that GLP-1 receptor-directed scintigraphy may be a new method for the detection of insulinomas in vivo.
View on Springer
The development of nanobodies for therapeutic applications.
TLDR
The structural properties of nanobodies are described and focuses on their unique features, which distinguishes these molecules from other antibody formats and small-molecule drugs.
View on PubMed
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs.
TLDR
Preclinical data demonstrate that ALX-0081 combines a high efficacy with an improved safety profile compared with currently marketed antithrombotics.
View on PubMed
Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
TLDR
ALX-0081 specifically inhibits platelet adhesion to the vessel wall, and may control platelet aggregation and subsequent clot formation without increasing bleeding risk, in studies performed with patients undergoing percutaneous coronary intervention (PCI).
View on Springer
Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study.
  • J. Suh, B. Stea, E. Shaw
  • Medicine
    Journal of clinical oncology : official journal…
  • 15 July 2004
TLDR
The addition of RSR13 to WBRT was well tolerated and led to a 22% reduction in the risk of death for all pts.
View on PubMed
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.
TLDR
It is demonstrated that ALX-0681 can successfully treat and prevent the most important hallmarks of acquired TTP without evidence of a severe bleeding risk, and offers an attractive new therapeutic option for acquired T TP in the clinical setting.
View on PubMed
Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
View on PubMed
OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA
TLDR
In patients with active RA, rapid and strong effects on the IL-6 pathway were observed and associated with a strong clinical response and the use of modelling enabled a rational study design with 3 biologically effective dose levels.
View on BMJ
The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura.
  • J. Holz
  • Biology
    Transfusion and apheresis science : official…
  • 1 June 2012
View on PubMed
Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions
TLDR
It is suggested that the dose of etoposide should be reduced in elderly patients and/or in individuals with impaired renal function, especially in those exhibiting general risk factors such as reduced liver function with regard to the polychemotherapy.
View on Springer
...
...